[Fundamental and clinical studies of cefpiramide in the field of obstetrics and gynecology].
Cefpiramide (CPM, SM-1652), a new cephem antibiotic, was fundamentally and clinically studied. The following results were obtained. Serum and internal genital tissue levels of CPM were measured following intravenous drip infusion of 1 g. High serum levels of 30 micrograms/ml and tissue levels of more than 4 micrograms/g were at least maintained for 8 hours. Favourable transfer of CPM into the pelvic dead space exudate was observed. The exudate level was 7.25 micrograms/ml on average even at 8 hours after intravenous drip infusion. A total of 6 cases comprising 4 with Bartholin's cyst, 1 with pelvic peritonitis and 1 with lymphocyst was treated with CPM at a dose of 0.5-2 g twice daily by intravenous injection or intravenous drip infusion. The clinical response was excellent in 1 case and good in 5 cases. Side effects and abnormal laboratory findings due to the drug were not noted.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D001826:Body Fluids / Q000032:analysis; D002511:Cephalosporins / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D010388:Pelvis / Q000032:analysis*; D010462:Peptostreptococcus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects
D002511:Cephalosporins; C036666:cefpiramide